The Patent Finder
US

Novel Opioid Antagonists

US 8,580,788 Term ended
OverviewFamilyAssignmentsSources & methods

Term ended Oct 25, 2026 · High confidence

Filed May 24, 2012 as application 13/479,622 · Granted Nov 12, 2013
Base term, 20 years from filing
Today
20 years from filing
Term ended Oct 25, 2026
2006 2026
Clock starts
Oct 25, 2006
Term ended
Oct 25, 2026
Granted
Nov 12, 2013
base term after the term ends fee events Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,538,110, to Oct 25, 2026. The term already ends on or before that date, so the cap shortened nothing.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees were paid, so no fee lapse ended it. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Oct 25, 2006, when application 11/552,827, the earliest non-provisional in its chain, was filed (this one was filed May 24, 2012)Oct 25, 2026High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 7,538,110)resolves to Oct 25, 2026, no earlier than this term, so no changeHigh confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events3 of 3 maintenance fees paidterm endedHigh confidence
Computed term endThe steps above, in orderOct 25, 2026High confidence

Partial family

US 7,538,110In force
Apr 2027
Apr 2027
US 8,278,323In force
Nov 2027
Nov 2027
US 8,580,788this patent
Oct 2026
Oct 2026
Application 13/950,853No file history here
not computed
not computed
US 8,895,560Term ended
no later than Oct 2026
no later than Oct 2026
Partial: 1 of the 5 has no file history here, so its row comes from the patent's own record or names the application alone. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Nov 20, 2012
Reel 29339, frame 669
Cubist Pharmaceuticals, Inc.; Adolor Corporation; Calixa Therapeutics, Inc.; Cubist Pharmaceuticals Holdings, Inc.; Cubist Pharmaceuticals U.S.Royal Bank of Canada, as Administrative AgentSecurity Agreement
Jul 9, 2015
Reel 36046, frame 153
Adolor CorporationMerck Sharp & Dohme Corp.Nunc Pro Tunc Assignment
Jul 24, 2015
Reel 36180, frame 70
Royal Bank of Canada, as Administrative AgentCalixa Therapeutics, Inc.; Adolor Corporation; Cubist Pharmaceuticals, Inc.Release of Security Interest
Jul 24, 2015
reel/frame not recorded
Royal Bank of Canada, as Administrative AgentCalixa Therapeutics, Inc.Release of Security Interest
Jul 24, 2015
reel/frame not recorded
Royal Bank of Canada, as Administrative AgentAdolor CorporationRelease of Security Interest
Jul 24, 2015
reel/frame not recorded
Royal Bank of Canada, as Administrative AgentCubist Pharmaceuticals, Inc.Release of Security Interest
Aug 8, 2022
Reel 61102, frame 145
Merck Sharp & Dohme Corp.Merck Sharp & Dohme LLCMerger

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited